戴维医疗(300314) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 was ¥141,399,028.33, representing a 3.13% increase year-over-year, while the year-to-date revenue decreased by 2.55% to ¥392,655,821.72[5] - Net profit attributable to shareholders for Q3 2025 was ¥21,641,148.48, a significant increase of 28.96% compared to the same period last year, and a year-to-date increase of 14.71% to ¥72,617,842.77[5] - Basic earnings per share for Q3 2025 was ¥0.0751, up 28.82% year-over-year, with diluted earnings per share also at ¥0.0751[5] - Total operating revenue for the current period is CNY 392,655,821.72, a decrease of 2.8% from CNY 402,925,721.56 in the previous period[18] - Net profit for the current period is CNY 72,617,842.77, an increase of 14.5% compared to CNY 63,307,872.06 in the previous period[19] - Earnings per share (EPS) increased to CNY 0.2521 from CNY 0.2198, representing a growth of 14.4%[20] Assets and Liabilities - Total assets at the end of Q3 2025 reached ¥1,443,616,126.33, reflecting a 2.38% increase from the end of the previous year[5] - Current assets totaled CNY 879,256,716.39, down from CNY 901,714,271.97 at the beginning of the period, indicating a decrease of approximately 2.5%[14] - Non-current assets increased to CNY 564,359,409.94 from CNY 508,368,642.73, reflecting a growth of about 11%[15] - The total liabilities decreased to CNY 216,567,496.67 from CNY 232,387,523.93, showing a reduction of approximately 6.8%[15] - Total liabilities decreased to CNY 225,021,267.57 from CNY 241,765,545.70, a reduction of 6.9%[16] Cash Flow - The company's cash flow from operating activities for the year-to-date period was ¥14,804,238.40, showing a 5.51% increase[5] - Cash flow from operating activities generated a net amount of CNY 14,804,238.40, slightly up from CNY 14,030,641.34 in the previous period[21] - Cash and cash equivalents at the end of the period were CNY 391,479,629.63, up from CNY 345,230,914.85, indicating an increase of approximately 13.4%[14] Investments - Investment income for Q3 2025 was ¥12,924,163.21, a remarkable increase of 1,579.01% compared to the previous period[8] - Investment income improved significantly to CNY 12,924,163.21 from a loss of CNY 873,836.79 in the previous period[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,297, with the top shareholder holding 45.81% of the shares[9] - Total equity attributable to shareholders increased to CNY 1,218,594,858.76 from CNY 1,168,317,369.00, reflecting a growth of 4.0%[16] Other Financial Metrics - The company received government subsidies amounting to ¥2,107,947.15 during the reporting period, contributing to its financial performance[6] - Other income rose to CNY 9,284,788.67 from CNY 7,517,469.38, an increase of 23.5%[19] - Deferred income increased to CNY 3,850,905.84 from CNY 3,371,835.46, marking a rise of 14.2%[16] Operational Changes - The company reported a 49.16% increase in accounts receivable, totaling ¥39,412,724.03, primarily due to increased credit limits for distributors[8] - The company experienced a 69.76% increase in prepayments, amounting to ¥20,208,693.76, attributed to higher prepayments for testing, exhibitions, and consulting services[8] - Inventory increased to CNY 219,844,431.26 from CNY 182,135,010.43, marking a growth of about 20.7%[14] - The company’s long-term equity investments decreased slightly to CNY 48,372,544.79 from CNY 50,327,967.68, a decline of about 3.9%[15] Audit Information - The company did not undergo an audit for the third quarter financial report[23]